镥[177Lu] PSMA-617 治疗对转移性前列腺癌导致的骨髓抑制的积极影响。
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
机构信息
From the *Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany; and †Urological Center Bonn, Bonn, Germany.
出版信息
Clin Nucl Med. 2016 Jun;41(6):478-80. doi: 10.1097/RLU.0000000000001195.
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.
一位 75 岁的男性患有去势抵抗性前列腺癌，前列腺特异性抗原（PSA）水平不断升高。在镭放射性核素治疗期间，他出现严重的骨髓抑制。因此，他因这种尚未获批的治疗方法而获得同情用药许可，使用 Lu-PSMA 进行治疗。Lu-PSMA 治疗开始时，需要反复输血（BT）。最后一次 BT 后 6 个月，进行了 3 个周期的 Lu-PSMA 治疗后，他的血细胞计数稳定下来。他不再需要 BT，PSA 水平也保持降低。
Zotero 插件